Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

Next Previous
Trial Profile

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cobicistat (Primary) ; Plixorafenib (Primary)
  • Indications Anaplastic astrocytoma; CNS cancer; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma; Solid tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms FORTE
  • Sponsors Fore Biotherapeutics

Most Recent Events

  • 22 May 2025 According to a Fore Biotherapeutics media release, company announced a $38 million Series D-2 financing. This $38 million adds to the $75 million raised as part of the earlier Series D and D-1 financings, for an aggregate total to date of $113 million for this Series D financing. Proceeds from the financing will be used to advance the registration-intended FORTE Master Protocol, a global Phase 2 clinical trial.
  • 30 Apr 2025 Trial design presented at 116th Annual Meeting of the American Association for Cancer Research.
  • 30 Apr 2025 According to Fore Biotherapeutics media release, Karisa Schreck, M.D., Ph.D will present trial design of this study at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO),

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top